Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
J Diabetes Complications
; 32(12): 1113-1117, 2018 Dec.
Article
em En
| MEDLINE
| ID: mdl-30318163
ABSTRACT
AIMS:
Obesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.METHODS:
Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30â¯mL/min/1.73â¯m2) were randomized 11 to receive once-daily oral dose of bardoxolone methyl (20â¯mg) or placebo.RESULTS:
BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7â¯kg; 95% CI -6.0 to -5.3â¯kg; pâ¯<â¯0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control.CONCLUSIONS:
Bardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Ácido Oleanólico
/
Glicemia
/
Peso Corporal
/
Diabetes Mellitus Tipo 2
/
Insuficiência Renal Crônica
/
Circunferência da Cintura
/
Obesidade
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article